循环游离DNA检测在结直肠癌诊治中应用的研究进展
摘要
循环游离DNA(ccf-DNA)是指存在于血液、游离于细胞之外的DNA片段。ccf-DNA检测正逐渐成为肿瘤筛查、早期诊断、预后评估以及抗癌治疗有效性监测的重要方法。通过相对无创方法获得的ccf-DNA可代替通过有创手段获得的结直肠癌(CRC)活检标本。ccf-DNA作为一种无创潜在肿瘤标志物在CRC早期诊断、疾病进展、疗效监测中有较高的应用价值。
引文
[1]Jeon SY,Kim WK,Kim H.Molecular classification of colorectal cancers and clinical Application[J].Korean J Gastroenterol,2016,68(6):297-302.
[2]Robertson EG,Baxter G.Tumour seeding following percutaneous needle biopsy:the real story[J].Clin Radiol,2011,66(11):1007-1014.
[3]Mandel P,Métais P.Les acides nucleiques du plasma sanguin chez lhomme[J].C R Seances Soc Biol Fil,1948,142(3-4):241-243.
[4]Leon SA,Shapiro B,Sklaroff DM,et al.Free DNA in the serum of cancer patients and the effect of therapy[J].Cancer Res,1977,37(3):646-650.
[5]Stroun M,Anker P,Lyautey J,et al.Isolation and characterization of DNA from the plasma of cancer patients[J].Eur J Cancer Clin Oncol,1987,23(6):707-712.
[6]Sotenson G,Pribish D,Valone F,et al.Soluble normal and mutated DNA sequences from single-copy genes in human blood[J].Cancer Epidraaiol Biomarkers Prev,1994,3(1):67-71.
[7]Nawroz H,Koch W,Anker P,et al.Microsatellite alterations in serum DNA of head and neck cancer patients[J].Nat Med,1996,2(9):1035-1037.
[8]Vitale I,Galluzzi L,Castedo M,et al.Mitotic catastrophe:a mechanism for avoiding genomic instability[J].Nat Rev Mol Cell Biol,2011,12(6):385-392.
[9]Delgado PO,Alves BC,Gehrke Fde S,et al.Characterization of cell-free circulating DNA in plasma in patients with prostate cancer[J].Tumour Biol,2013,34(2):983-986.
[10]Bendich A,Wilczok T,Borenfreund E.Circulating DNA as a possible factor in oncogenesis[J].Science,1965,148(3668):374-376.
[11]Kidess E,Heirich K,Wiggin M,et al.Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel,high-sensitivity multiplexed mutation detection platform[J].Oncotarget,2015,6(4):2549-2561.
[12]Fernandes CL,Kim SB,Matos D.Cytokeratins and carcinoembryonic antigen in diagnosis,staging,and prognosis of colorectal adenocarcinoma[J].World J Gastroenterol,2005,11(5):645-648.
[13]Florent M,Safia EM,Celine G.Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load[J].Transl Oncol,2013,6(3):319-328.
[14]Flamini E,Mercatali L,Nanni O,et al.Free DNA and carcinoembryonic antigen serum levels:an important combination for diagnosis of colorectal cancer[J].Clin Cancer Res,2006,12(23):6985-6988.
[15]Schwarzenbach H,Stoehlmacher J,Pantel K,et al.Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer[J].Ann N Y Acad Sci,2008,1137:190-196.
[16]Frattini M,Gallino G,Signoroni S.Quantitative analysis of plasma DNA in colorectal cancer patients:a novel prognostic tool[J].Ann NY Acad Sci,2006:1075:185-190.
[17]Spindler KG,Appelt AL,Pallisgaard N,et al.KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer[J].Br J Cancer,2013,109(12):3067-3072.
[18]Diehl F,Schmidt K,Choti MA,et al.Circulating mutant DNA to assess tumor dynamics[J].Nat Med,2008,14(9):985-990.
[19]Kuo YB,Chen JS,Fan CW.Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer[J].Clin Chim Acta,2014,433:284-289.
[20]Mansour H.Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection[J].Front Genet,2014,5:182.
[21]Hecht JR,Douillard JY,Schwartzberg L,et al.Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer[J].Cancer Treat Rev,2015,7372(15):103-106.
[22]Spindler KL,Pallisgaard N,Andersen RF,et al.Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cellfree DNA,KRAS and BRAF in the plasma[J].Inte J Cancer,2014,135(9):2215-2222.
[2]Robertson EG,Baxter G.Tumour seeding following percutaneous needle biopsy:the real story[J].Clin Radiol,2011,66(11):1007-1014.
[3]Mandel P,Métais P.Les acides nucleiques du plasma sanguin chez lhomme[J].C R Seances Soc Biol Fil,1948,142(3-4):241-243.
[4]Leon SA,Shapiro B,Sklaroff DM,et al.Free DNA in the serum of cancer patients and the effect of therapy[J].Cancer Res,1977,37(3):646-650.
[5]Stroun M,Anker P,Lyautey J,et al.Isolation and characterization of DNA from the plasma of cancer patients[J].Eur J Cancer Clin Oncol,1987,23(6):707-712.
[6]Sotenson G,Pribish D,Valone F,et al.Soluble normal and mutated DNA sequences from single-copy genes in human blood[J].Cancer Epidraaiol Biomarkers Prev,1994,3(1):67-71.
[7]Nawroz H,Koch W,Anker P,et al.Microsatellite alterations in serum DNA of head and neck cancer patients[J].Nat Med,1996,2(9):1035-1037.
[8]Vitale I,Galluzzi L,Castedo M,et al.Mitotic catastrophe:a mechanism for avoiding genomic instability[J].Nat Rev Mol Cell Biol,2011,12(6):385-392.
[9]Delgado PO,Alves BC,Gehrke Fde S,et al.Characterization of cell-free circulating DNA in plasma in patients with prostate cancer[J].Tumour Biol,2013,34(2):983-986.
[10]Bendich A,Wilczok T,Borenfreund E.Circulating DNA as a possible factor in oncogenesis[J].Science,1965,148(3668):374-376.
[11]Kidess E,Heirich K,Wiggin M,et al.Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel,high-sensitivity multiplexed mutation detection platform[J].Oncotarget,2015,6(4):2549-2561.
[12]Fernandes CL,Kim SB,Matos D.Cytokeratins and carcinoembryonic antigen in diagnosis,staging,and prognosis of colorectal adenocarcinoma[J].World J Gastroenterol,2005,11(5):645-648.
[13]Florent M,Safia EM,Celine G.Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load[J].Transl Oncol,2013,6(3):319-328.
[14]Flamini E,Mercatali L,Nanni O,et al.Free DNA and carcinoembryonic antigen serum levels:an important combination for diagnosis of colorectal cancer[J].Clin Cancer Res,2006,12(23):6985-6988.
[15]Schwarzenbach H,Stoehlmacher J,Pantel K,et al.Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer[J].Ann N Y Acad Sci,2008,1137:190-196.
[16]Frattini M,Gallino G,Signoroni S.Quantitative analysis of plasma DNA in colorectal cancer patients:a novel prognostic tool[J].Ann NY Acad Sci,2006:1075:185-190.
[17]Spindler KG,Appelt AL,Pallisgaard N,et al.KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer[J].Br J Cancer,2013,109(12):3067-3072.
[18]Diehl F,Schmidt K,Choti MA,et al.Circulating mutant DNA to assess tumor dynamics[J].Nat Med,2008,14(9):985-990.
[19]Kuo YB,Chen JS,Fan CW.Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer[J].Clin Chim Acta,2014,433:284-289.
[20]Mansour H.Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection[J].Front Genet,2014,5:182.
[21]Hecht JR,Douillard JY,Schwartzberg L,et al.Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer[J].Cancer Treat Rev,2015,7372(15):103-106.
[22]Spindler KL,Pallisgaard N,Andersen RF,et al.Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cellfree DNA,KRAS and BRAF in the plasma[J].Inte J Cancer,2014,135(9):2215-2222.